At this point of the evolving RWD landscape, we thought it appropriate to begin to broadly assess the use of real world data.
Our survey is open now.
While the impact and legacy of the very much on-going pandemic most acutely hits those infected, their families and friends, and the frontline healthcare providers, one clear legacy of this extraordinary moment will be how it helped show real world data is a critical component of the life sciences industry’s future.
There is now a daily public consumption of complex, evolving real world health data to an extraordinary degree. From the original goal of “flattening the curve” to rolling averages, and rates for testing, cases, hospitalizations, deaths, vaccinations and more, data inserts itself into the daily discourse up, down, and across society. At the same time, real world data continues to increasingly impact virtually every facet of what the life sciences industry does - from R&D strategy to commercialization – across therapeutic areas.
Again, your support of our survey is appreciated.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.